© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
January 18, 2022
Naomi B. Haas, MD, discusses efforts to improve care in locally advanced renal cell carcinoma through research in the neoadjuvant setting.
January 17, 2022
Eric Jonasch, MD, offers his advice for physicians treating patients with renal cell carcinoma.
Sarah Elizabeth Yentz, MD, discusses what sequencing research and novel treatment development is needed to advance the metastatic renal cell carcinoma paradigm.
January 13, 2022
Ziad Bakouny, MD, MSc, highlights efforts to gain an understanding of the biology and genomic drivers of the rare and aggressive form of kidney cancer.
On this episode of Cleveland Clinic’s Cancer Advances podcast, urologic surgeon Steven Campbell, MD, PhD, discusses the longstanding controversy between partial nephrectomy and radical nephrectomy for patients with localized kidney cancer.
January 07, 2022
The trial is exploring tivozanib combined with the investigational HIF2α-inhibitor NKT2152 in patients with renal cell carcinoma who have not responded to or have relapsed from prior treatments.
January 05, 2022
The phase 3 CONTACT-03 trial is specifically accruing patients with inoperable, locally advanced or metastatic renal cell carcinoma with disease progression after receiving an immune checkpoint inhibitor as the immediate prior therapy.
January 04, 2022
At a median follow-up of 10.4 months (IQR: 5.8-16.4), SAbR extended drug efficacy by more than 6 months in 70% of mRCC patients (14 out of 20; 95% CI: 49.9-90.1).
January 03, 2022
Eric Jonasch, MD, shares insight on the most pivotal developments in renal cell carcinoma over the past few years.
A retrospective analysis of the phase 3 CheckMate-214 trial showed a treatment-free survival advantage with the immunotherapy combination versus the targeted therapy sunitinib in patients with advanced renal cell carcinoma.